I’ve been keeping an eye on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe REGN has a lot to offer. Basically, it is a company with great financial health as well as a an impressive track record of performance. Below, I’ve touched on some key aspects you should know on a high level. For those interested in digging a bit deeper into my commentary, read the full report on Regeneron Pharmaceuticals here.
Flawless balance sheet with proven track record
In the previous year, REGN has ramped up its bottom line by 70%, with its latest earnings level surpassing its average level over the last five years. This strong performance generated a robust double-digit return on equity of 26%, which is what investors like to see! REGN’s strong financial health means that all of its upcoming liability payments are able to be met by its current cash and short-term investment holdings. This implies that REGN manages its cash and cost levels well, which is a key determinant of the company’s health. REGN seems to have put its debt to good use, generating operating cash levels of 3.48x total debt in the most recent year. This is also a good indication as to whether debt is properly covered by the company’s cash flows.
For Regeneron Pharmaceuticals, I’ve put together three pertinent factors you should look at:
- Future Outlook: What are well-informed industry analysts predicting for REGN’s future growth? Take a look at our free research report of analyst consensus for REGN’s outlook.
- Valuation: What is REGN worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether REGN is currently mispriced by the market.
- Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of REGN? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.